Jump to content

Alovudine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 14:48, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Alovudine
Clinical data
ATC code
  • none
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13F2N2O4
Molar mass244.22 g/mol g·mol−1
3D model (JSmol)
  • O=C/1NC(=O)N(\C=C\1C)[C@@H]2O[C@@H]([C@@H](F)C2)CO
  • InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1 checkY
  • Key:UXCAQJAQSWSNPQ-XLPZGREQSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Alovudine was an antiviral agent being developed by Medivir, which was discontinued after a Phase II trial in 2005 due to toxicity. It was a DNA polymerase inhibitor.[1]

References

  1. ^ Georgopapadakou N. Discontinued drugs in 2005: anti-infectives. Expert Opin Investig Drugs. 2007 Jan;16(1):1-10. PMID 17155849